America Great Health (AAGH)
USD 0.0
(-18.18%)
USD 0.0
(-18.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.82 Million USD | 14.97% |
| 2022 | 4.19 Million USD | 284.71% |
| 2021 | 1.09 Million USD | 398.33% |
| 2020 | 218.9 Thousand USD | 30.22% |
| 2019 | 168.1 Thousand USD | 39.45% |
| 2018 | 120.54 Thousand USD | 131.85% |
| 2017 | 51.99 Thousand USD | -96.13% |
| 2016 | 1.34 Million USD | 32.07% |
| 2015 | 1.01 Million USD | 187.78% |
| 2014 | 353.27 Thousand USD | 42.81% |
| 2013 | 247.36 Thousand USD | 314.14% |
| 2012 | 59.73 Thousand USD | 520.65% |
| 2011 | 9624.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 5.2 Million USD | 2.06% |
| 2024 Q1 | 4.95 Million USD | 2.74% |
| 2024 Q2 | 5.1 Million USD | 2.92% |
| 2023 Q3 | 4.66 Million USD | 3.99% |
| 2023 FY | 4.82 Million USD | 14.97% |
| 2023 Q4 | 4.82 Million USD | 3.41% |
| 2023 Q1 | 4.38 Million USD | 4.53% |
| 2023 Q2 | 4.48 Million USD | 2.27% |
| 2022 Q3 | 3.56 Million USD | 11.6% |
| 2022 FY | 4.19 Million USD | 284.71% |
| 2022 Q4 | 4.19 Million USD | 17.57% |
| 2022 Q2 | 3.19 Million USD | 148.44% |
| 2022 Q1 | 1.28 Million USD | 18.02% |
| 2021 Q3 | 472.16 Thousand USD | -23.82% |
| 2021 Q2 | 619.76 Thousand USD | 181.65% |
| 2021 Q4 | 1.09 Million USD | 131.03% |
| 2021 FY | 1.09 Million USD | 398.33% |
| 2021 Q1 | 220.04 Thousand USD | 0.52% |
| 2020 Q1 | 171.05 Thousand USD | 1.76% |
| 2020 Q2 | 181.14 Thousand USD | 5.9% |
| 2020 Q3 | 182.56 Thousand USD | 0.78% |
| 2020 FY | 218.9 Thousand USD | 30.22% |
| 2020 Q4 | 218.9 Thousand USD | 19.91% |
| 2019 Q1 | 127.16 Thousand USD | 5.49% |
| 2019 FY | 168.1 Thousand USD | 39.45% |
| 2019 Q3 | 159.35 Thousand USD | 5.0% |
| 2019 Q4 | 168.1 Thousand USD | 5.49% |
| 2019 Q2 | 151.76 Thousand USD | 19.34% |
| 2018 Q1 | 65.25 Thousand USD | 25.5% |
| 2018 Q3 | 87.42 Thousand USD | 12.51% |
| 2018 FY | 120.54 Thousand USD | 131.85% |
| 2018 Q4 | 120.54 Thousand USD | 37.88% |
| 2018 Q2 | 77.7 Thousand USD | 19.09% |
| 2017 Q2 | 783.41 Thousand USD | 1.83% |
| 2017 FY | 51.99 Thousand USD | -96.13% |
| 2017 Q4 | 51.99 Thousand USD | 205.24% |
| 2017 Q3 | 17.03 Thousand USD | -97.83% |
| 2017 Q1 | 769.34 Thousand USD | -42.7% |
| 2016 Q2 | 1.16 Million USD | -4.04% |
| 2016 Q3 | 1.22 Million USD | 5.4% |
| 2016 Q4 | 1.34 Million USD | 9.58% |
| 2016 Q1 | 1.21 Million USD | 19.17% |
| 2016 FY | 1.34 Million USD | 32.07% |
| 2015 Q4 | 1.01 Million USD | 17.0% |
| 2015 Q2 | 711.26 Thousand USD | 38.9% |
| 2015 Q1 | 512.06 Thousand USD | 44.95% |
| 2015 FY | 1.01 Million USD | 187.78% |
| 2015 Q3 | 868.95 Thousand USD | 22.17% |
| 2014 Q2 | 49.89 Thousand USD | -80.76% |
| 2014 Q1 | 259.36 Thousand USD | 4.85% |
| 2014 Q3 | 201.58 Thousand USD | 304.05% |
| 2014 Q4 | 353.27 Thousand USD | 75.25% |
| 2014 FY | 353.27 Thousand USD | 42.81% |
| 2013 Q2 | 180.36 Thousand USD | 5.59% |
| 2013 Q4 | 247.36 Thousand USD | 12.81% |
| 2013 FY | 247.36 Thousand USD | 314.14% |
| 2013 Q1 | 170.82 Thousand USD | 185.98% |
| 2013 Q3 | 219.28 Thousand USD | 21.58% |
| 2012 Q4 | 59.73 Thousand USD | 491.1% |
| 2012 Q3 | 10.1 Thousand USD | 0.0% |
| 2012 FY | 59.73 Thousand USD | 520.65% |
| 2011 FY | 9624.00 USD | 0.0% |
| 2011 Q4 | 9624.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -103.071% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 87.605% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 96.362% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -73.622% |
| Better Therapeutics, Inc. | 23.84 Million USD | 79.763% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 41.756% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 51.626% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 81.681% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 84.819% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 93.051% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 39.275% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 89.971% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 96.933% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -37.622% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 77.337% |
| Molecular Templates, Inc. | 31.17 Million USD | 84.521% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 61.446% |
| NexImmune, Inc. | 5.08 Million USD | 5.099% |
| Orgenesis Inc. | 35.53 Million USD | 86.422% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 70.779% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -1711.078% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -110.208% |
| Scopus BioPharma Inc. | 7.45 Million USD | 35.274% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 99.024% |
| Statera Biopharma, Inc. | 22.67 Million USD | 78.723% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 55.791% |
| Trevena, Inc. | 48.26 Million USD | 90.003% |
| Vaxxinity, Inc. | 30.94 Million USD | 84.407% |
| Vaccinex, Inc. | 5.94 Million USD | 18.799% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -145.129% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 87.426% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -74.719% |